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Abstract
Background Butyrylcholinesterase (BChE) is an α-glyco-
protein synthesized in the liver. Its serum level decreases
in many clinical conditions such as acute and chronic
liver damage, inflammation, injury and infections, and
malnutrition.
Methods and results This review collects the main evi-
dence on the emerging role of butyrylcholinesterase as a
prognostic marker of liver and nonliver diseases as well
as a marker of protein-energy malnutrition and obesity.
In fact, serum concentrations and BChE activity seem to
accurately reflect the availability of amino acidic sub-
strates and/or derangement in protein synthesis due to
hepatocellular damage. In cancer, with or without liver
impairment, serum BChE levels serve as an accurate
functional and prognostic indicator, useful for monitoring
clinical and therapeutic interventions according to
patients’ prognosis. In the absence of inflammation,
BChE could also serve as an index of the effectiveness
of nutritional support.
Conclusions Serum BChE assessment should be includ-
ed in routine clinical diagnostic procedures to evaluate
patient clinical conditions, in particular in cases of in-
flammation and/or protein-energy malnutrition.
Keywords Butyrylcholinesterase . Prognostic marker .
Liver and nonliver diseases . Protein-energy
malnutrition . Obesity
1 Introduction
1.1 What is butyrylcholinesterase?
Cholinesterase represents a group of enzymes that hydro-
lyze acetylcholine and other choline esters. There are two
main types of cholinesterase with different biochemical
properties: true or specific cholinesterase or acetylcholines-
terase found in all excitable tissues (central and peripheral
nervous system and muscles) and in erythrocytes. It is a
high-turnover enzyme with high affinity for acetylcholine,
inhibited at high concentrations of acetylcholine, and with
low affinity for noncholine esters [1].
The other one is the nonspecific or pseudocholinesterase or
serum cholinesterase or butyrylcholinesterase which hydroly-
ses both choline and aliphatic esters. Butyrylcholinesterase
(BChE) is an α-glycoprotein found in the central and periph-
eral nervous system, in most tissues, and in the liver. It has
lower affinity for acetylcholine and is not inhibited by high
concentrations of acetylcholine [1]. BChE half-life is about
12 days [2, 3], and its normal value ranges between 5,900 and
13,200 IU/L. An increased activity of this enzyme has been
reported in obesity, diabetes, uremia, hyperthyroidism, and in
hyperlipidemic subjects [4–6].
A small proportion of healthy population is lacking in
plasma BChE, due to a genotype aberration; studies carried
out in Europe indicate a 3–4% prevalence of congenital serum
BChE deficiency [7]. BChE is synthesized in the liver: a
hepatocellular impairment will reflect a decreased enzyme
activity. In fact, plasma levels fall in acute and chronic liver
damage, cirrhosis, and liver metastases, being a biochemical
marker of organ damage. Low plasma BChE levels have also
been found in protein-energy malnutrition, during stress and
(chronic and acute) inflammation, and in other clinical con-
ditions [8]. On the other hand, plasma BChE activity was
significantly elevated in both type 1 and 2 diabetes, compared
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with the control subjects. In addition, BChE activity was
positively associated with serum concentrations of cholesterol
and triglycerides and with measures of overweight, obesity,
and body fat distribution [9, 10].
2 Aim of the review
There are few and not updated data in literature on the
significance of BChE variations according to some physio-
logical and pathological conditions, but also according to
our clinical experience, BChE seems to have a prognostic
role in different diseases. As it will be described in the text,
the prognostic value of BChE varies from disease to disease,
being of outcome, discharge, survival, weaning off artificial
nutrition, and disease progression.
The review aims to collect the main, past, and recent eviden-
ces reported in the literature on the emerging role of BChE as a
prognostic marker in some liver and nonliver diseases, as well as
in protein-energy malnutrition and obesity (Table 1).
3 Protein-energy malnutrition and inflammation
Protein-energy malnutrition (PEM) may have important ad-
verse effects on clinical outcomes; for this reason, nutrition-
al assessment should regularly be part of diagnostic
procedures in acute and chronic diseases. Recent evidence
suggests that either acute or chronic inflammatory diseases
are key contributing factors in the pathophysiology of PEM.
In clinical practice, nutritional status may be compro-
mised in conditions of (1) pure chronic starvation without
inflammation (e.g., clinical conditions such as anorexia
nervosa), (2) chronic diseases or conditions that impose
sustained inflammation of a mild to moderate degree (e.g.,
organ failure, inflammatory bowel diseases, rheumatoid ar-
thritis, advanced cancer, etc,), and (3) acute disease or injury
states with marked inflammatory response (e.g., major in-
fection, burns, trauma, or closed head injury) [11]. On the
other hand, stress and inflammation can influence appetite
and gastrointestinal motility, promoting through anorexia
the vicious cycle: chronic–acute disease and PEM [12].
As well known, critical illness or injury promotes an in-
flammatory response that has a rapid, catabolic effect on fat-
free (or lean) body mass. On the other hand, loss of muscle
mass and function may insidiously occur, and in the chronic
disease state, even over months to years. The presence of
inflammation often limits the effectiveness of nutritional inter-
ventions while the associated malnutrition may compromise
the clinical response to medical therapy. The anorexic patient
and/or chronic disease-related malnutrition is prone to quickly
deteriorate with any additional acute inflammatory event and
warrants close follow-up.
“Positive” acute-phase proteins, such as C-reactive protein
(CRP), directly rise with inflammatory disease activity; “nega-
tive” acute-phase proteins (albumin, prealbumin, and transfer-
rin) inversely respond: their circulating levels decrease in
response to injury and inflammation and increase during the
recovery phase [13, 14]. These proteins reflect either cytokine-
induced stress, catabolism, and anorexia, which in turn affect
patient's clinical conditions and nutritional status. Therefore,
the evaluation and monitoring of the preexisting inflammatory
status appears crucial.
For its short half-life, some authors speculate on the useful-
ness of serum BChE as a nutritional and prognostic marker,
rapidly changing with general clinical conditions and nutrition-
al status [1]. BChE levels are strongly influenced by inflam-
mation, sensitively decreasing in the acute inflammatory phase
and promptly increasing when inflammation improves [15].
Serum BChE was already known to decrease in patients with
PEM, probably due to inadequate availability of substrates for
its synthesis rather than to hepatocellular failure [1].
In malnourished children with marasmus and edematous
undernutrition (or kwashiorkor), serum BChE, total proteins,
and albumin levels are lower than those measured in normal
children; these values tend to increase after 3 weeks of nutri-
tional rehabilitation [16]. In a similar study on 200 malnour-
ished infants, the degree of edema resulted to be inversely
related to BChE and albumin levels; a similar trend of serum
BChE values was observed in undernourished adults [17].
In hospitalized patients diagnosed with protein-energy
visceral or nonvisceral undernutrition, BChE levels resulted
low and significantly correlated with transferrin, albumin,
and cholesterol, particularly in visceral malnutrition. Viscer-
al undernutrition is a condition strictly linked with low
values of visceral proteins such as albumin, transferrin,
and total lymphocyte count [18].
In conclusion, BChE levels seem to strictly correlate
with the outcome of malnourished patients, being low
during the inflammatory phases, in the case of inade-
quate availability of substrates, or in the presence of
edema and recovering with the amelioration or resolution
of these conditions. In particular, in case of malnutrition,
BChE activity seems a reliable indicator of patient con-
ditions, better than albumin, for the latter is more strong-
ly influenced by inflammation.
3.1 Geriatric
As regard to the healthy geriatric population, no correlation
has been found between BChE levels and advanced age,
suggesting that age per se does not seem to be associated
with reductions in esterase enzyme activity. This finding is
particularly useful if we consider that the older population is
frequently under medical treatments and that esterases are
primarily involved in drug metabolism [19].
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BChE has also been considered as a useful biomarker for the
diagnosis and monitoring of malnutrition and in general as a
prognostic indicator in the elderly [20, 21]. In literature, plasma
esterases were found to decrease in frail older people and during
acute illness: in 30 elderly patients, with increasing patient
frailty, CRP, interleukin-6 (IL-6), and tumor necrosis factor
alpha (TNF-α) significantly increased, while BChE activity
significantly dropped (p<0.005). In addition, BChE activity
resulted to be significantly and negatively correlated with the
proinflammatory cytokines IL-6 and TNF-α [18]. Also, in
geriatric patients, BChE is a valid prognostic indicator, strictly
related with nutritional status and inflammation.
3.2 Malignancy
Advanced cancer is a condition in which mild to moderate
inflammation is frequent and interacts with various degree
of PEM. Plasma BChE levels resulted to be decreased in
advanced cancer patients, with or without hepatic involve-
ment: the lowest activity has been found in patients with
hepatic metastases, despite the normality of other liver func-
tion tests [22]. One of the possible mechanisms responsible
for BChE activity decrease in cancer patients could be
secondary anorexia accompanying malignancy [23].
In a study by our group in 152 terminal cancer patients
with peritoneal carcinosis, BChE serum levels resulted to be
a survival predictive factor together with albumin and Kar-
nofsky index [24]. In 126 hospitalized cancer patients, un-
dergoing a nutritional assessment at admission and after
1 week, it was observed that, in case of a serum BChE level
below 1,900 IU/L at entry, the risk of developing relevant
weight loss, hypoproteinemia, and hypoalbuminemia during
hospitalization resulted to be significantly higher [25]. In
another study of patients with head and neck or uterine
cervix cancer who are in radiation therapy, BChE activity
showed to be an affective prognostic marker: BChE activity
resulted to be lower in all patients before starting radiation
therapy, increased as radiotherapy progressed, and remained
in the normal range at 6 months of follow-up in those
patients with no detectable disease activity [26].
Bozzetti et al. observed that serum BChE, rapid turnover
proteins (transferrin, thyroxin-binding prealbumin, and retinol-
binding protein), body weight, and nitrogen balance improved
during nutritional support in cancer patients. According to recent
evidences, in these conditions too, the improvement of serum
proteins levels, more than a specific nutritional recovery, could
primarily reflect the reduced inflammation and the improvement
of general clinical conditions [27].
In stress conditions, such as cancer cachexia, there are met-
abolic derangements where synthesis and catabolism are both
higher than in unstressed malnourished patients or in fasted
normal volunteers. In 246 patients with non-Hodgkin’s lympho-
ma, the same authors wondered about a possible relationship
between nutritional status (weight, weight loss, albumin, BChE
activity, lymphocyte count) and tumor growth (evaluated with
the rate of incorporation of 3H-labeled thymidine in the tumor
tissue). The only significant association was found between low
serum BChE activity (index of a poor nutritional status and
presence of inflammation) and high incorporation of 3H-labeled
thymidine, demonstrating also that the maintenance of a good
nutritional status has no deleterious effect on tumor growth [28].
Finally, in 75 patients who underwent macroscopic curative
resection for pancreatic cancer, low serum BChE levels corre-
lated with nerve plexus invasion of the primary tumor, thus
representing a poor prognostic index. Patients with low serum
BChE levels also manifested systemic disorders, including poor
performance status, anemia, and hypoalbuminemia [29]. In
patients with cancer, BChE levels seem to correlate with disease
activity and nutritional status and could represent a valid surviv-
al predictive factor.
3.3 Hemodialysis
Uremic patients undergoing hemodialysis are often catabolic
and malnourished; they commonly feed on inadequate quanti-
ties of protein and calories and may be protein-depleted, with a
mixed marasmus/kwashiorkor-like pattern of protein-energy
malnutrition. Malnutrition in uremia can be affected by many
factors: uremic toxicity, infections, hypercatabolism, loss of
amino acids during dialysis, abnormalities in amino acid and
protein metabolism, and decreased protein synthesis in liver.
Also, in patients on chronic hemodialysis, BChE was used as
prognostic marker, in addition to the other traditional parameters
(anthropometric indices, serum protein content, immune re-
sponse indexes) [30, 31]. Serum protein, albumin, C3, blood
lymphocyte count, and BChE generally resulted to be decreased
in chronically uremic patients undergoing conservative or dial-
ysis treatments [30]. The short-term intravenous supplementa-
tion of essential amino acids during dialysis determined a
significant (p<0.05) increase in body weight, arm muscle cir-
cumference, and serum albumin as well as BChE levels.
The circulating levels of IL-6, a proinflammatory cytokine
inducing the production of acute-phase proteins and involved
in weight loss, resulted to be significantly higher in patients
undergoing hemodialysis than in healthy volunteers and sig-
nificantly and inversely related with serum albumin (r0−0.4,
p00.006) and BChE (r0−0.51, p00.001) levels [31]. Patients
in dialysis have a condition of chronic inflammation and
malnutrition. Also, in this case, BChE is directly related with
albumin and inversely related with inflammation.
3.4 Inflammatory bowel disease
As previously discussed, in acute inflammatory diseases, both
serum BChE and albumin appeared to be inversely related with
acute-phase proteins, due to the action of proinflammatory
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cytokines [32]. Together with serum albumin concentration,
BChE levels were also proposed as direct markers of malnutri-
tion and indirect index of inflammatory activity in Crohn’s
disease (CD). In fact, BChE activity and albumin concentration
resulted to be significantly lower in patients with active CD
than in those with quiescent disease (p<0.001), and both
proteins were significantly lower in malnourished than in
well-nourished patients [33].
3.5 Critically ill patients
In severely burnt patients and in critically ill patients, the
absorption of nutrients in the upper regions of the intestine
resulted to be slightly impaired for gastrointestinal dysmotility;
serum BChE activity was found to be also decreased, suggest-
ing subnormal biosynthetic processes [34]. In septic patients,
serum levels of albumin, cholesterol, and (BChE) resulted to be
significantly lower than in the control group [35].
In 133 consecutive adult patients receiving necessity
orthotopic liver transplantation (OLT), predictors of 12-
month mortality included lower BChE levels (2,900±
1.880 versus 3,700±2.020 IU/L, p00.026). According to
score-based medical urgency criteria pre-OLT, BChE is a
predictor of short-term post-OLT survival and may be help-
ful as a bedside score in pre-OLT clinical management,
outcome prediction, and decision making [36].
3.6 Anorexia nervosa
Anorexia nervosa (AN) represents a pure form of marasmus-
like malnutrition. In AN, despite the occurrence of adaptive
metabolic mechanisms due to chronic underfeeding, many
organs and systems can negatively be affected. Regarding
liver function, available evidences suggest that abnormalities
in serum liver enzymes may occur and some cases of acute
liver failure have been described. In AN, a mild to moderate
increase in liver enzymes is expected to reflect a fatty liver,
which is typical of several protein-energy malnutrition states.
In these clinical circumstances, hepatic steatosis, among
others, could have been the consequence of an imbalance
between hepatic triacylglycerol synthesis and secretion and
decreased lipoprotein synthesis, due to decreased amino acid
availability [37]. Abnormal serum concentrations of BChE
and other liver enzymes have frequently been found, not only
in the severe cases of hospitalized AN patients but also in
outpatients with either AN or eating disorder not otherwise
specified (ED-NOS). LowBChE activity was observed by our
group in 97 underweight outpatients with AN and in 66 with
ED-NOS when compared with 56 controls; these results have
been interpreted as a marker of the effects of primary malnu-
trition on liver function and lack of protein substrates.
In two extreme cases of AN, patients developed se-
vere and acute liver failure with a marked increase of
serum transaminases and a dramatic reduction of BChE
levels. Following nutritional recovery, BChE rapidly in-
creased [38].
In conclusion, in this study, low serum BChE activity has
been reported in AN, independent of the age, weight, or
BMI of patients, thus suggesting a predominant causal role
for decreased nutrient availability rather than a relationship
with changes in body composition [39].
3.7 Enteral and parenteral nutrition
Enteral and parenteral nutrition are medical therapies, often
lifesaving for home and hospitalized patients. Together with
other anthropometric, biochemical (serum albumin, prealbu-
min, transferrin, cholesterol, thyroxine-binding protein,
retinol-binding protein) and hematological (lymphocyte
count) parameters, serum BChE also appears to be a poten-
tial reliable prognostic marker, rapidly and sensitively
changing with the variations of the patient’s nutritional
status and general clinical conditions [40].
In four patients on long-term home total parenteral nutri-
tion (TPN), hospitalized in our clinical ward for catheter-
related bloodstream infection, the septic state and TPN
interruption, even when partially replaced by peripheral
parenteral nutrition, induced a fast deterioration of the
patient’s general clinical conditions. In all patients, de-
creased blood levels of prealbumin, albumin, cholesterol,
lymphocyte count, and BChE levels were observed. In the
same patients, after the resolution of infection and TPN
restoration, BChE levels promptly and sensitively increased
(from +54.3 up to +124.8 %).
In these case reports, serum BChE represents a useful and
sensitive marker of the amelioration of patient’s clinical
conditions after the resolution of infection and the restora-
tion of TPN through the central venous catheter. Moreover,
in these four patients, a close correlation between serum
BChE and albumin was found [41]. The same correlation
was found in 17 seriously ill surgical patients who received
TPN for 4–21 days [42].
In a retrospective examination of 312 clinical records
of patients before undergoing enteral and parenteral
nutrition, Donini et al. found that the percentage of
negative outcomes (death or interruption of parenteral/
enteral nutrition, due to the worsening of clinical con-
ditions) was higher in subjects >80 years of age, with
higher comorbidities; reduced levels of albumin, preal-
bumin, lymphocyte count, and BChE; and higher levels
of C-reactive protein [40].
Similarly to prealbumin, whose half-life is much shorter
than albumin (2–3 versus 21 days), BChE serum levels are
not only reduced by malnutrition but also by inflammation
and liver diseases and resulted to be significantly correlated
with negative outcome [43].
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4 Liver and nonliver diseases
Regarding liver diseases, a decreased BChE activity reflects
a hepatocellular impairment; similarly, recovery was
evidenced by a gradual increase of BChE levels. During
and after treatment with high dose interferon alpha per-
formed in 101 patients with chronic HCV infection, total
cholesterol levels gradually increased reaching normal val-
ues in responders. Serum BChE activity pattern paralleled
that of serum cholesterol and was related with serum albu-
min, as already seen in chronic liver diseases [1, 44].
Serum BChE levels decrease in liver dysfunction as a con-
sequence of reduced synthesis, in comparison with other liver
enzymes whose levels increase because of an increased release
from damaged cell membranes. The traditional liver function
tests may result abnormal in other diseases, not related with
liver dysfunction. For example, high level of serum transami-
nases can be the consequence of their release by nonliver
tissues (i.e., heart and muscles); the increase of the serum
alkaline phosphatase activity may result from physiological or
pathological enzyme production from nonliver tissue (i.e., bone
and placenta). In addition, serum bilirubin may rise because of
increased erythrocyte breakdown and reduced albumin concen-
tration due to increased renal or intestinal loss (i.e., nephrotic
syndrome or protein-loosing entheropathy) [45].
Ogunkeye et al. evaluated if serum BChE activity could help
in differentiating between liver and nonliver diseases in three
groups of subjects: group 1, liver disease with at least four out of
five abnormal liver function tests (aspartate transaminase (AST),
alanine transaminase (ALT), alkaline phosphatase, total biliru-
bin, and albumin); group 2, nonliver disease with at least two
abnormal liver function tests, and group 3, healthy subjects.
Group 2 patients presented serum BChE activity within normal
range for healthy individuals, but the mean BChE value was
lower compared to the control group; however, the difference
was not statistically significant. On the other hand, patients with
liver diseases (group 1) had serumBChE activity well below the
reference interval for healthy subjects. The predominant hepatic
source of serum BChE activity, the marked decreased synthesis
with hepatocyte dysfunction, and its restoration with hepatocyte
recovery suggested that serum BChE activity might be a more
specific marker of liver dysfunction than the more traditional
liver function tests [23].
5 AIDS
In patients with AIDS and abnormal D-xylose test, due to
small intestinal dysfunction, BChE activity, total serum pro-
teins, albumin, and cholesterol were significantly lower than
in patients with a normal D-xylose absorptive test. Also, in this
condition, BChE activity correlated with impairment of body
composition and reflected protein-energy malnutrition [46].
6 HELLP syndrome
Pseudocholinesterase activity was reduced in pregnant
women with HELLP syndrome and gradually increased
with liver function recovery. There was a negative correla-
tion between BChE activity and inflammatory response
intensity, as measured by granulocyte count, ESR, body
temperature, and IgA levels [47, 48].
7 Obesity and metabolic syndrome
BChE takes part in the protidosynthetic pathway and regulates
the degradation of butyrylcholine, an intermediate of lipid
metabolism, as demonstrated also by the close relation between
serum BChE levels, cholesterol, and triacylglycerols [49].
BChE seems to be broadly involved in the pathophysiol-
ogy of the metabolic syndrome. Its enzymatic activity is
positively associated with cardiovascular risk factors: it is
higher in patients who have hypertension, hyperlipidemia,
and high body weight. On the other hand, it is inversely
related to cardiovascular mortality: individuals with very
low BChE activity have a higher mortality rate; BChE levels
result low in patients who suffered acute myocardial infarc-
tion or underwent treatment with beta blockers [50, 51].
In experimental studies, during fattening in pigs, BChE
activity significantly increased, probably due to an adaptive
response of the hepatic synthesis of this enzyme to the
increased lipid metabolism. Mice fed on a restricted diet
had significantly lower serum BChE levels than mice fed a
normal diet ad libitum; at the same time, an increase in
BChE activity was observed in lean mice fed on a high
carbohydrate diet. On the other hand, a marked reduction
(40 %) in BChE activity occurred in the liver of genetically
diabetic mice when starved for 24 h [6, 52, 53].
Liver BChE activity directly varied according to the
protein content in the diet: high-protein diets produced the
greatest increase in BChE activity in the liver compared to
high-carbohydrate or high-fat diets [54].
BChE activity was significantly elevated in both type 1 and
type 2 diabetes comparedwith the control subjects (p<0.001);
in these patients, serum BChE was correlated with serum
fasting triacylglycerol concentration (p<0.001) [55].
BChE may play a role in lipid metabolism, whether
directly or through a synergistic action with cholesterol
esterase. Several investigators have found significant rela-
tionships between cholinesterase activity and triacylglycer-
ols, HDL cholesterol, and LDL cholesterol [6, 55–59].
One important issue arising from these findings is wheth-
er higher BChE activity is a cause or a consequence of
dyslipidemia and metabolic syndrome. Several published
reports on animal and human studies did not give a clear
answer [60–64]. Interventions that primarily increase or
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decrease blood lipids tend to have the same effect on BChE,
but inhibition of BChE activity in vivo has been shown not
to decrease lipid concentrations [61, 65–68]. BChE activity
was reduced after treatment with bezafibrate but did not
significantly change after treatment with statins [59].
In 1,097 healthy subjects, serum BChE activity was mea-
sured and metabolic syndrome risk factors assessed. Serum
BChE activity correlated with fasting insulin levels (r00.266,
p<0.001) and insulin resistance (HOMA-R) index (r00.292,
p<0.001) and resulted higher in individuals with risk factors for
metabolic syndrome. In two other studies on diabetic patients,
BChE was found to be significantly correlated with serum
insulin (r00.622, p<0.001), C-peptide (r00.652, p<0.001),
and free fatty acid (r00.821, p<0.001). Circumstantial evidence
was provided demonstrating that insulin resistance and an in-
creased flux of free fatty acids from adipose tissue to the liver
stimulated the hepatic synthesis of serum BChE; these results
suggest the involvement of PChE in the pathophysiology of the
metabolic syndrome [49].
Also, the association with AST, ALT, and gamma-
glutamyltransferase (GGT) activities, which are known to
be associated with insulin resistance, probably reflects an
association between BChE activity and the metabolic syn-
drome, of which fatty liver is a feature. Overweight patients
with type 2 diabetes displayed significantly increased activ-
ities of serum ALT (172 % of mean values in controls), GGT
(253 %), and BChE (139 %) and a strong correlation of
BChE with serum triglycerides (r00.760, p<0.001) [5].
Increased BChE activity has been observed in nonobese
as well as obese patients with fatty liver, whereas obese
subjects without liver changes showed levels in the upper
normal range. In subjects with fatty liver submitted to a low
caloric diet, BChE activity decreased in parallel with the
improvement of hepatic steatosis [69].
A striking parallel was also noted between plasma lecithin–
cholesterol acyltransferase and serum BChE activity: both
enzymes resulted to be lower than normal in liver disease and
higher in endogenous hypertriglyceridemia and were also pos-
itively correlated with serum cholesterol and triglycerides, thus
suggesting that both liver enzymes might be induced by an
increased turnover of serum lipids and lipoproteins [70].
Blood pressure, as well, might be influenced causally by
BChE because its substrate acetylcholine induces vasodilation
by triggering nitric oxide release via endothelial muscarinic
cholinergic receptors [71]. An excess of cholinesterase activ-
ity in the metabolic syndrome could also adversely affect
endothelial function and ultimately increase blood pressure.
The gene for plasma cholinesterase is on chromosome 3;
in addition to the known gene variants leading to low
enzyme activity, a proportion of individuals show an addi-
tional cholinesterase electrophoresis band associated with an
increased enzyme activity. This occurs with a frequency of
8 to 10 % among Europeans and is ascribed to the effects of
another gene, cholinesterase (serum) 2 (PChE2), located on
chromosome 5. It has been hypothesized that the region of
chromosome 5 contains a gene for a protein that binds to
BChE and increases its activity. Another explanation could
be that high serum lipid concentrations may induce stereo-
scopic alteration in the enzymatic configuration that modi-
fies BChE activity or altered expression of the enzyme-
encoding gene that determines BChE concentration and
activity [56].
8 Discussion
Serum concentrations and BChE activity seem to accurately
reflect the availability of amino acidic substrates and/or a
derangement in the protein synthesis due to hepatocellular
damage; additionally, it seems adequate to distinguish liver
and nonliver diseases. In cancer, with or without liver im-
pairment, stress starvation stimulates an inflammatory cas-
cade which blocks the synthesis of BChE, albumin, and
other visceral proteins in favor of acute-phase protein syn-
thesis. In these conditions, serum BChE results an accurate
functional and prognostic indicator, useful for monitoring
the clinical and therapeutic intervention according to the
patient’s survival expectance [72].
In the absence of inflammation, BChE could be also a
valid index of nutritional support effectiveness. In patients
with primary malnutrition, either in excess or in defect,
BChE levels result strictly correlated with the classical
indicators of the nutritional status such as albumin, lympho-
cyte count, cholesterol, and transferrin. Due to the large
range of normality of serum BChE, this parameter is more
suitable for repeated monitoring rather than single
determination.
Clinical judgment certainly represents a fundamental
hinge to combine with serum BChE evaluation as indicator
of the severity of disease and/or protein-energy malnutrition
the necessity of a nutritional support. Moreover, it is always
preferable to associate BChE evaluation with other prog-
nostic markers.
BChE activity assay seems to be a valid biological
marker of malnutrition, inflammation, and liver synthetic
ability with a relatively low cost and high clinical infor-
mative power [1]. Serum BChE determination is a routine
clinical laboratory test, scheduled in all laboratory panels
at hospital admission as well as for outpatient evaluation;
on demand, it is also possible to add this test in the urgent
exams’ panels. Its cost is similar to that of other routine
exams (serum glucose, urea, creatinine dosage, etc.), in-
cluding the assay of albumin, prealbumin, transferrin, and
lymphocyte count. BChE may therefore enter in a cluster
of selected prognostic parameters, useful to complete the
clinical judgment.
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9 Conclusion
Serum BChE assessment should be included in routine clinical
diagnostic procedures to evaluate patient clinical conditions, in
particular in cases of inflammation and/or protein-energy mal-
nutrition. This parameter has a prognostic value varying from
disease to disease; for example, it indicates inadequate avail-
ability of substrates for liver synthesis and positively correlates
with the effectiveness of nutritional support in case of malnu-
trition; BChE has a survival predictive role in cancer patients
and seems to correlate with disease progression. Finally, re-
duced levels of BChE suggested negative outcomes (death or
worsening of clinical conditions) in patients on artificial nutri-
tion. Conversely to what happens in case of malnutrition,
during metabolic syndrome (diabetes, hypertension, hyperlip-
idemia) and/or hepatic steatosis, BChE positively correlates
with the presence of mild inflammation
In obesity, metabolic syndrome, lipid metabolism impair-
ment, and fatty liver, BChE activity can also provide infor-
mation on the patient’s metabolism, habitual diet, and finally
on the specific response to treatment.
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